Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: Comparison with osteosarcoma cells

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 2, 2015, Pages 231-243

  Tacar, Oktay ^a   Indumathy, Sivanjah ^a   Tan, Mei Lin ^b   Baindur Hudson, Swati ^a   Friedhuber, Anna M ^c   Dass, Crispin R ^d,e  

^a VICTORIA UNIVERSITY   (Australia)

^b St Vincent's Health ^*  (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Curtin Biosciences Research Precinct   (Australia)

^e CURTIN UNIVERSITY   (Australia)

Author keywords

apoptosis; autophagy; Bax; Beclin 1; cardiotoxicity

Indexed keywords

BECLIN 1; DOXORUBICIN; PROTEIN BAX; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER CELL LINE; CELL VIABILITY; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG MEGADOSE; ELECTRON MICROSCOPY; HEART; HEART MUSCLE CELL; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PROSTATE CANCER CELL LINE; RAT; SKIN; SMALL INTESTINE; STOMACH; TESTIS; ANIMAL; BAGG ALBINO MOUSE; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; HEART MUSCLE; METABOLISM; OSTEOSARCOMA; PROSTATIC NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BCL-2-ASSOCIATED X PROTEIN; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DOXORUBICIN; FEMALE; HEART; HUMANS; LIVER; MALE; MEMBRANE PROTEINS; MICE, INBRED BALB C; MYOCARDIUM; MYOCYTES, CARDIAC; OSTEOSARCOMA; PROSTATIC NEOPLASMS; RATS; SKIN;

EID: 84921653730     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12324     Document Type: Article

References (41)

1. The American Cancer Society. Facts and Figures. Atlanta, GA: ACS Publishing, 2012.
2. Croce CM,. Oncogenes and cancer. N Engl J Med 2008; 358: 502-511.
3. Shiozawa Y, et-al. Cancer stem cells and their role in metastasis. Pharmacol Ther 2013; 138: 285-293.
4. Tan ML, et-al. Osteosarcoma: conventional treatment vs gene therapy. Cancer Biol Ther 2009; 8: 106-117.
5. Tacar O, et-al. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2013; 65: 157-170.
6. Ashley N, Poulton J,. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun 2009; 378: 450-455.
7. Carvalho C, et-al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009; 16: 3267-3285.
8. Chatterjee K, et-al. Doxorubicin cardiomyopathy. Cardiology 2010; 115: 155-162.
9. Umlauf J, Horký M,. Molecular biology of doxorubicin-induced cardiomyopathy. Exp Clin Cardiol 2002; 7: 35-39.
10. Nithipongvanitch R, et-al. Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)? Antioxid Redox Signal 2007; 9: 1001-1008.
11. Giuliani CM, Dass CR,. Autophagy and cancer: taking the 'toxic' out of cytotoxics. J Pharm Pharmacol 2013; 65: 777-789.
12. Gewirtz DA,. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
13. Drevs J, et-al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004; 24: 1759-1763.
14. Akiyama T, et-al. PEDF regulates osteoclasts via osteoprotegerin and RANKL. Biochem Biophys Res Commun 2010; 391: 789-794.
15. Tan ML, et-al. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials 2010; 31: 541-551.
16. Ek ET, et-al. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res 2007; 25: 1671-1680.
17. Ta HT, et-al. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials 2009; 30: 3605-3613.
18. Clark JC, et-al. RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer 2011; 117: 3517-3528.
19. Dass CR, Choong PF,. Gene therapy for osteosarcoma: steps towards clinical studies. J Pharm Pharmacol 2008; 60: 405-413.
20. Zhu W, et-al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009; 119: 99-106.
21. Wencker D, et-al. A mechanistic role for cardiomyocyte apoptosis in heart failure. J Clin Invest 2003; 111: 1497-1504.
22. Tan ML, et-al. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model. J Pharm Pharmacol 2013; 65: 35-43.
23. Rushing DA, et-al. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994; 74: 834-841.
24. Sishi BJ, et-al. Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart. Exp Biol Med 2012; 237: 219-226.
25. Auvinen PK, et-al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 2010; 96: 271-275.
26. Kaushal V, et-al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2004; 2: 327-334.
27. McLoon LK, et-al. Doxorubicin chemomyectomy as a treatment for cervical dystonia: histological assessment after direct injection into the sternocleidomastoid muscle. Muscle Nerve 1998; 21: 1457-1464.
28. Dekaney CM, et-al. Regeneration of intestinal stem/progenitor cells following doxorubicin treatment of mice. Am J Physiol Gastrointest Liver Physiol 2009; 297: G461-G470.
29. Sakr SA, Abo-El-Yazid SM,. Effect of fenugreek seed extract on adriamycin-induced hepatotoxicity and oxidative stress in albino rats. Toxicol Ind Health 2012; 28: 876-885.
30. Giuliani CM, Dass CR,. Metabolic stress and cancer: is autophagy the common denominator and a feasible target? J Pharm Pharmacol 2014; 66: 597-614. doi: 10.1111/jphp.12191.
31. Lennernäs B, et-al. Chemotherapy and antiangiogenesis-drug-specific, dose-related effects. Acta Oncol 2003; 42: 294-303.
32. Russell LD, Russell JA,. Short-term morphological response of the rat testis to administration of five chemotherapeutic agents. Am J Anat 1991; 192: 142-168.
33. Dass CR, et-al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 2005; 22: 643-652.
34. Dass CR, et-al. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis 2006; 23: 367-380.
35. Balli E, et-al. Effect of melatonin on the cardiotoxicity of doxorubicin. Histol Histopathol 2004; 19: 1101-1108.
36. Broadhead ML, et-al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011; 2011: 959248. doi: 10.1155/2011/959248.
37. Djavaheri-Mergny M, et-al. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 2010; 29: 1717-1719.
38. Wirawan E, et-al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 2010; 1: e18. doi: 10.1038/cddis.2009.16.
39. Devarajan E, et-al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002; 21: 8843-8851.
40. Kang R, et-al. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011; 18: 571-580.
41. Tacar O, Dass CR,. Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes? J Pharm Pharmacol 2013; 65: 1577-1589.